Download full-text PDF |
Source |
---|
Cardiol J
December 2024
Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea.
Eur J Pediatr
November 2024
Arrhythmias, Inherited Cardiac Diseases and Sudden Death Unit, Hospital Sant Joan de Déu, Esplugues de Llobregat, 08950, Barcelona, Catalonia, Spain.
Resuscitation
September 2024
Department of Emergency Medicine and Rocky Mountain Poison and Drug Safety, Denver Health, Denver, CO, USA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address:
JAMA
July 2024
Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
Front Cardiovasc Med
May 2024
Cardiovascular Center, Center of Heart Failure and Center of Genetic Heart Diseases, Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Background: Lacosamide is frequently used as a mono- or adjunctive therapy for the treatment of adults with epilepsy. Although lacosamide is known to act on both neuronal and cardiac sodium channels, potentially leading to cardiac arrhythmias, including Brugada syndrome (BrS), its adverse effects in individuals with genetic susceptibility are less understood.
Case: We report a 33-year-old female with underlying epilepsy who presented to the emergency department with a four-day history of seizure clusters, and was initially treated with lacosamide therapy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!